Claims for Patent: 10,254,564

Summary for Patent: 10,254,564

Title:	Contact lens use in the treatment of an ophthalmologic condition
Abstract:	The disclosure relates to the use of contact lenses for treating ophthalmologic conditions, such as presbyopia, induced myopia, computer vision syndrome, insufficient accommodation, or a condition associated with insufficient accommodation. The contact lens may be selected based on a measured sagittal depth and/or eccentricity of the cornea. When fitted, fluid may accumulate between the cornea of the eye and the contact lens The lens may exhibit a sufficient amount of apical clearance such that when the wearer blinks, the lens moves no more than 1 mm on the eye. The lens may be structured such that bubbles greater than 0.5 mm in diameter are prevented from forming between the contact lens and the eye. The contact lens may be used in combination with a suitable bioactive agent providing for enhanced visual correction.
Inventor(s):	Grant; Stuart C. (Los Angeles, CA), Osio Hernandez-Pons; Alberto (Mexico, MX), Rinehart; John Michael (Peoria, AZ)
Assignee:	Osio Corporation (Coronado, CA)
Application Number:	14/800,469
Patent Claims:	1. A method of fitting a contact lens for an eye of a subject, comprising: measuring a radius of curvature at the flattest corneal meridian of the eye; selecting a contact lens having an optic zone with a curvature that varies from a curvature at the flattest corneal meridian of the eye by between 2.0 and 6.0 diopters; and applying the contact lens to the eye, wherein upon blinking of the eye, the contact lens does not move by more than 1 mm. 2. The method of claim 1, wherein selecting a contact lens comprises selecting a contact lens for the eye of a subject having an ophthalmologic condition selected from the group consisting of presbyopia, computer vision syndrome (CVS), and insufficient accommodation. 3. The method of claim 2 further comprising applying a therapeutic agent between the contact lens and the eye. 4. The method of claim 3, wherein the therapeutic agent comprises one or more corneal softening agents selected from the group consisting of hyaluronidase, chondroitinase ABC, chondroitinase AC, endo B-galactosidase (keratanase), stromelysin (MM3), bacterial collagenase, interstitial collagenase (MM1), and gelatinase (MM2). 5. The method of claim 4, wherein the one or more softening agents comprises hyaluronidase and bacterial collagenase. 6. The method of claim 5, wherein the one or more softening agents comprises 1 to 10 USP units per mL hyaluronidase and 5 to 15 USP units per mL bacterial collagenase. 7. The method of claim 1, wherein measuring the radius of curvature at the flattest corneal meridian of the eye comprises using a keratometer to measure the radius of curvature. 8. The method of claim 1, wherein the contact lens prevents bubbles greater than 0.5 mm in diameter from forming between the contact lens and the eye. 9. The method of claim 1, wherein the contact lens has an optic zone with a curvature that varies from a curvature at the flattest corneal meridian of the eye by between 3.5 and 5.5 diopters. 10. The method of claim 1 further comprising applying a therapeutic agent between the contact lens and the eye. 11. A method of fitting a contact lens for an eye of a subject, comprising: measuring a radius of curvature at the flattest corneal meridian of the eye; selecting a contact lens having an optic zone with a curvature that varies from a curvature at the flattest corneal meridian of the eye by between 2.0 and 6.0 diopters; and applying the contact lens to the eye, wherein the contact lens prevents bubbles greater than 0.5 mm in diameter from forming between the contact lens and the eye. 12. The method of claim 11, wherein selecting a contact lens comprises selecting a contact lens for the eye of a subject having an ophthalmologic condition selected from the group consisting of presbyopia, computer vision syndrome (CVS), and insufficient accommodation. 13. The method of claim 12 further comprising applying a therapeutic agent between the contact lens and the eye. 14. The method of claim 13, wherein the therapeutic agent comprises one or more corneal softening agents selected from the group consisting of hyaluronidase, chondroitinase ABC, chondroitinase AC, endo B-galactosidase (keratanase), stromelysin (MM3), bacterial collagenase, interstitial collagenase (MM1), and gelatinase (MM2). 15. The method of claim 14, wherein the one or more softening agents comprises hyaluronidase and bacterial collagenase. 16. The method of claim 15, wherein the one or more softening agents comprises 1 to 10 USP units per mL hyaluronidase and 5 to 15 USP units per mL bacterial collagenase. 17. The method of claim 11, wherein measuring the radius of curvature at the flattest corneal meridian of the eye comprises using a keratometer to measure the radius of curvature. 18. The method of claim 11, wherein the contact lens has an optic zone with a curvature that varies from a curvature at the flattest corneal meridian of the eye by between 3.5 and 5.5 diopters. 19. The method of claim 11, wherein upon blinking of the eye, the contact lens does not move by more than 1 mm. 20. The method of claim 11 further comprising applying a therapeutic agent between the contact lens and the eye.

Details for Patent 10,254,564

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2032-08-10
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2032-08-10
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2032-08-10
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2032-08-10
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2032-08-10